

Fitlife Brands, Inc. (FTLF)

Nasdaq; healthcare; SIC 2833, Medicinal Chemicals & Botanical Products; CIK 0001374328

Fitlife Brands, Inc. FTLF; healthcare	
Grade	B A B C D E second fifth of 371 graded peers percentile 35.1; sampling error 2.5 points; lower is stronger
Rank	131 of 371
Profitability	C percentile 55.3
Solvency	C percentile 53.5
Growth and financing	A/B percentile 21.5
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$106.3M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: dilution, short runway, distress, fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Apr 21, 2026 171 days before the rescans; latest periodic filing 10-Q received Aug 13, 2026
Last close	\$8.56 2026-10-08; market equity \$80.4M
Price used in grade	None



B, the elk
second fifth of its sector; letters are fifths of the 371 graded peers


Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: A/B from Jun 21, 2025, B from Aug 21, 2025, B/C from Jun 21, 2026, B from Aug 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

FitLife Brands, Inc. (the "Company") is a provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, the "NDS Products"); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the

"iSatori Products"); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the "MRC Products"); (iv) MusclePharm; and (v) Irwin Naturals, Applied Nutrition, and Nature's Secret (together, the "Irwin Products").


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 55.3						
Gross profitability		29.6%	32.2%	50.4	372	2025-12-31
Return on invested capital		not computable	9.3%			required facts have no common fiscal period end
Accruals ratio		(1.4%)	(6.6%)	78.3	811	2025-12-31
Gross margin stability, five years		2.2 pts	2.8 pts	37.2	243	2025-12-31
Solvency, sleeve percentile 53.5						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		2.44	(0.31)	26.8	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			required facts have no common fiscal period end
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		1.53x	2.96x	80.3	839	2025-12-31
Growth and financing, sleeve percentile 21.5						
Revenue growth, three-year compound		41.4%	10.0%	15.9	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 9
Reinvestment rate		54.9%	37.1%	42.7	104	2025-12-31
Asset growth, three years		60.5%	2.1%	5.8	704	2025-12-31
Net share issuance, one year		not computable	2.5%			prior share count is 27 days earlier

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
126	Apyx Medical Corp. (APYX)	33.8	B	
127	Tandem Diabetes Care Inc. (TNDM)	34.1	B	
128	BrightSpring Health Services, Inc. (BTSG)	34.5	B	
129	BrightSpring Health Services, Inc. (BTSGU)	34.5	B	
130	Glaukos Corp. (GKOS)	34.9	B	fortress
				balance sheet
131	Fitlife Brands, Inc. (FTLF) <	35.1	B	
132	Insméd Inc. (INSM)	35.4	B	
133	Establishment Labs Holdings Inc. (ESTA)	35.7	B	fortress
				balance sheet
134	Ionis Pharmaceuticals Inc. (IONS)	35.9	B	
135	Biocryst Pharmaceuticals Inc. (BCRX)	36.2	B	fortress
				balance sheet
136	Tenet Healthcare Corp. (THC)	36.5	B	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(49.5%)	8.0%	14
Distance from 52-week high	(58.1%)	(31.4%)	19
EBIT to enterprise value	8.4%	(1.5%)	89
Free cash flow yield	9.1%	(1.0%)	90
Book value to price	0.58	0.28	73
Sales to price	1.00	0.31	83
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.89)	(0.14)	14

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite

Days since last periodic filing

57 (10-Q received Aug 13, 2026)

Median daily dollar volume, 63 sessions

\$99,460

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$31.5M	2025-12-31	2026-03-31	10-K	0001437749-26-010680
2	assets	us-gaap:Assets	\$106.3M	2025-12-31	2026-03-31	10-K	0001437749-26-010680
3	net income	us-gaap:NetIncomeLoss	\$6.3M	2025-12-31	2026-03-31	10-K	0001437749-26-010680
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$7.4M	2025-12-31	2026-03-31	10-K	0001437749-26-010680
5	assets	us-gaap:Assets	\$58.5M	2024-12-31	2026-03-31	10-K	0001437749-26-010680
6	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$81.5M	2025-12-31	2026-03-31	10-K	0001437749-26-010680
7	gross profit	us-gaap:GrossProfit	\$28.1M	2024-12-31	2026-03-31	10-K	0001437749-26-010680
8	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$64.5M	2024-12-31	2026-03-31	10-K	0001437749-26-010680
9	gross profit	us-gaap:GrossProfit	\$21.4M	2023-12-31	2025-03-27	10-K	0001437749-25-009469
10	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$52.7M	2023-12-31	2025-03-27	10-K	0001437749-25-009469
11	gross profit	us-gaap:GrossProfit	\$12.0M	2022-12-31	2024-03-29	10-K	0001437749-24-010119
12	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$28.8M	2022-12-31	2024-03-29	10-K	0001437749-24-010119
13	gross profit	us-gaap:GrossProfit	\$12.5M	2021-12-31	2023-03-24	10-K	0001437749-23-007858
14	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$27.9M	2021-12-31	2023-03-24	10-K	0001437749-23-007858
15	current assets	us-gaap:AssetsCurrent	\$33.1M	2025-12-31	2026-03-31	10-K	0001437749-26-010680
16	current liabilities	us-gaap:LiabilitiesCurrent	\$21.6M	2025-12-31	2026-03-31	10-K	0001437749-26-010680
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$11.9M	2025-12-31	2026-03-31	10-K	0001437749-26-010680
18	operating income	us-gaap:OperatingIncomeLoss	\$10.1M	2025-12-31	2026-03-31	10-K	0001437749-26-010680
19	book equity	us-gaap:StockholdersEquity	\$43.6M	2025-12-31	2026-03-31	10-K	0001437749-26-010680
20	liabilities	us-gaap:Liabilities	\$62.7M	2025-12-31	2026-03-31	10-K	0001437749-26-010680
21	operating income	us-gaap:OperatingIncomeLoss	\$7.5M	2023-12-31	2025-03-27	10-K	0001437749-25-009469
22	interest expense	us-gaap:InterestExpense	\$1.0M	2023-12-31	2024-03-29	10-K	0001437749-24-010119
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$42,000	2025-12-31	2026-03-31	10-K	0001437749-26-010680
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$420,000	2025-12-31	2026-03-31	10-K	0001437749-26-010680
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$8.2M	2025-12-31	2026-03-31	10-K	0001437749-26-010680
26	income tax	us-gaap:IncomeTaxExpenseBenefit	\$1.9M	2025-12-31	2026-03-31	10-K	0001437749-26-010680
27	current assets	us-gaap:AssetsCurrent	\$18.1M	2024-12-31	2026-03-31	10-K	0001437749-26-010680
28	current liabilities	us-gaap:LiabilitiesCurrent	\$11.3M	2024-12-31	2026-03-31	10-K	0001437749-26-010680
29	assets	us-gaap:Assets	\$55.3M	2023-12-31	2025-03-27	10-K	0001437749-25-009469
30	assets	us-gaap:Assets	\$25.7M	2022-12-31	2024-03-29	10-K	0001437749-24-010119
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	9,391,072	2026-04-23	2026-04-21	10-K/A	0001437749-26-012937
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	9,391,072	2026-03-27	2026-03-31	10-K	0001437749-26-010680